Peptides for Disease Research

We’re rapidly producing custom peptides and peptide libraries for the major proteins of SARS-COV-2. With high quality products available fast for researchers combating Covid19, come and see Mimotopes for all of your peptide needs.

Custom Peptide Libraries

The advantage of our proprietary parallel synthesis technology is that Mimotopes can synthesise hundreds of peptides simultaneously, and thus greatly reduce the price and time to delivery.

High quality Peptide Libraries affordable prices

30 Years Experience

Mimotopes is the founder of peptide library technology. We have only continued to grow and learn over the decades – now our expertise is unrivaled.

We work tirelessly to stay ahead of the game to ensure, as always, that we supply the best possible products, including SARS-CoV-2 peptides.

Efficient & Economical Screening Solutions

PepsetTM PeptideLibraries have dozens of potential applications. With applications in covid19 vaccine and drug development, disease screening, and epitope mapping, a peptide library can be exclusively designed to your specifications, for your research. 

  • Discover crucial residues with an Alanine Scan Library
  • Map epitopes with an Overlapping Library
  • Narrow down the shortest active sequences with a Truncated Library

Dozens of Options to Customise

A standard PepSetTM Peptide Library can be supplied as with a precise length and offset designed to best suit your assays, but that’s not all. Modifications and labels can be applied to the termini or even within the sequence. Arrange a consultation to discuss your options and design your library.

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

✉ australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

 useast@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com


UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

  ✉ useast@mimotopes.com 
  ✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK/ Europe/ Africa/ Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Go to article: Home | Genomic projects exploit scaleGo to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Owen Mumford Company InsightGo to article: Owen MumfordGo to article: CommentGo to article: Disappointing results signal setbacks for Alzheimer’s treatmentsGo to article: Heart failure: charting the clinical trial landscape in the past decadeGo to article: Russia’s focus on domestic pharma production could shield it from sanctionsGo to article: Delayed EMA approval: improved safety or lack of access to therapeutics?Go to article: CMOs and US Government invest in continuous manufacturingGo to article: BaxterGo to article: CSafe GlobalGo to article: NiproGo to article: In DepthGo to article: Genomic projects exploit scale as clinical applications play catch-upGo to article: Tracing the rise of orphan drug designations over almost 40 yearsGo to article: How much does it hurt—measuring pain in clinical trialsGo to article: Neglected tropical diseases: non-profits lead the way as private sectors lagsGo to article: CMO Moves: Regulatory catalysts for drug manufacturing-JulyGo to article: Pfeiffer VacuumGo to article: Biolife SolutionsGo to article: In DataGo to article: Supply chain & logistics innovation among pharma companiesGo to article: Hiring boom in pharmaceutical industry IoT rolesGo to article: Regenerative medicine deals decreased in the pharma industryGo to article: Digitalization jobs in the pharmaceutical industryGo to article: EventsGo to article: Next issue